Cefixime 100mg/5mL, 200mg/5mL, 500mg/5mL; strawberry flavor; pwd for reconstitution. 400mg once daily or 200mg every 12 hrs. Gonorrhea: 400mg once. Infections due to Streptococcus pyogenes: treat for ...

SUPRAX (Cefixime) 400mg tablets by Lupin Pharmaceuticals Suprax (cefixime tablets, from Lupin) 400mg has been made available again for the treatment of susceptible bacterial infections, including ...

BALTIMORE, April 28 /PRNewswire/ -- Lupin Pharmaceuticals, Inc. announced today the launch of Suprax(R) 400mg Tablets (Cefixime USP) in the US. This line extension further extends the brand franchise ...

In the latest black eye for India's pharma industry, Lupin is recalling some 10,000 bottles of its Suprax antibiotic in the U.S. The pills fell short of standards for purity, the FDA said in a ...

Drug maker Lupin announced that it has received the new drug application (NDA) approval from the US health regulator to market its Suprax capsules in the strength of 400 mg in America. Lupin Group ...

Citalopram capsules are used to treat major depressive disorder in adults, while Cefixime capsules are indicated in the treatment of certain infections. Aurobindo also has received the green light ...

MUMBAI, April 15 (Reuters) - India's Lupin Ltd is recalling 9,210 bottles of infection-preventing drug Suprax which failed a purity test in the United States, the U.S. Food and Drug Administration ...

Lupin Ltd has informed BSE regarding a Press Release dated February 22, 2013 titled "Lupin Receives FDA Approval for New Drug Application for SUPRAX Oral Suspension, 500 mg/5mL". Lupin Pharmaceuticals ...

Shares of Lupin fell 3.5 percent intraday on Thursday as brokerage Morgan Stanley said it sees risk to Suprax (antibiotic drug) from the Aurobindo approval. Aurobindo on Wednesday has received final ...

The nationwide recall has been initiated by the company on 27 January. Photo: Bloomberg New Delhi: Drug major Lupin is voluntarily recalling 9,210 bottles of its antibiotic drug Suprax, used to treat ...

DUBLIN--(BUSINESS WIRE)--The "Suprax 2016 U.S. Promotional Report" report has been added to Research and Markets' offering. The 5 Key Questions Addressed by this Report: How many physicians were ...